SecSonar.com

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ascendis Pharma A/S (ASND) is a Biotechnology company based in DK with a market capitalization of $13.7B. Revenue grew 90.2% year-over-year and the company generated $43.6M in free cash flow. This page tracks ASND's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DK · 1.02K employees · IPO Jan 28, 2015

Valuation

Valuation & price

$237.21 · as of May 26, 2026 · -13.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$275$219$163Jul 25Dec 25Jul 26Jul 7, 25$175.98Jul 9, 25$175.71Jul 11, 25$174.96Jul 15, 25$174.75Jul 17, 25$177.20Jul 21, 25$168.02Jul 23, 25$170.14Jul 25, 25$167.47Jul 29, 25$163.32Jul 31, 25$173.50Aug 4, 25$184.15Aug 6, 25$182.60Aug 11, 25$195.97Aug 13, 25$191.08Aug 15, 25$198.32Aug 19, 25$194.62Aug 21, 25$192.80Aug 25, 25$190.37Aug 27, 25$193.01Aug 29, 25$194.27Sep 3, 25$200.02Sep 5, 25$205.91Sep 9, 25$202.91Sep 11, 25$197.67Sep 16, 25$197.24Sep 18, 25$199.37Sep 22, 25$196.42Sep 24, 25$193.28Sep 26, 25$191.99Sep 30, 25$198.81Oct 2, 25$200.97Oct 6, 25$210.83Oct 8, 25$210.13Oct 10, 25$209.55Oct 14, 25$208.71Oct 16, 25$207.03Oct 21, 25$200.59Oct 23, 25$201.01Oct 27, 25$203.23Oct 29, 25$205.71Oct 31, 25$201.60Nov 4, 25$208.24Nov 6, 25$199.28Nov 10, 25$196.01Nov 12, 25$199.22Nov 14, 25$204.40Nov 18, 25$217.13Nov 20, 25$209.55Nov 25, 25$206.65Nov 28, 25$212.33Dec 2, 25$202.16Dec 4, 25$208.58Dec 8, 25$207.12Dec 10, 25$201.24Dec 12, 25$220.42Dec 16, 25$212.11Dec 18, 25$199.80Dec 22, 25$209.43Dec 24, 25$212.81Dec 29, 25$211.02Jan 2, 26$213.29Jan 6, 26$209.29Jan 8, 26$208.75Jan 12, 26$208.76Jan 14, 26$217.32Jan 16, 26$205.83Jan 21, 26$216.66Jan 23, 26$235.39Jan 27, 26$238.80Jan 29, 26$223.95Feb 2, 26$223.59Feb 4, 26$219.73Feb 9, 26$222.03Feb 11, 26$221.49Feb 13, 26$216.32Feb 18, 26$226.83Feb 20, 26$225.00Feb 24, 26$234.99Feb 26, 26$228.99Mar 2, 26$242.09Mar 4, 26$241.38Mar 6, 26$240.65Mar 10, 26$240.52Mar 12, 26$229.01Mar 17, 26$228.06Mar 19, 26$223.82Mar 23, 26$218.06Mar 25, 26$220.90Mar 27, 26$216.95Mar 31, 26$228.73Apr 2, 26$229.25Apr 7, 26$220.48Apr 9, 26$241.71Apr 13, 26$248.55Apr 15, 26$241.71Apr 17, 26$244.48Apr 22, 26$231.05Apr 24, 26$229.27Apr 28, 26$222.08Apr 30, 26$229.38May 4, 26$228.71May 6, 26$235.90May 8, 26$238.66May 12, 26$237.65May 14, 26$245.49May 18, 26$237.64May 20, 26$241.34May 22, 26$247.05May 28, 26$237.47Jun 1, 26$218.82Jun 3, 26$216.79Jun 5, 26$210.45Jun 9, 26$213.23Jun 11, 26$215.60Jun 15, 26$223.29Jun 17, 26$231.15Jun 22, 26$228.00Jun 24, 26$238.01Jun 26, 26$260.75Jul 2, 26$274.50
$163.3252-week range$274.50
Loading valuation history…

Fundamentals

Key fundamentals

$13.7B

Market cap

90.2%

Revenue growth (YoY)

85.1%

Gross margin

$43.6M

Free cash flow (USD)

$255.6M

Net debt

4.7%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.6MFY 2017$1.5MFY 2018$10.6MFY 2019$13.4MFY 2020$7.0MFY 2021$7.8MFY 2022$51.2MFY 2023$266.7MFY 2024$363.6MFY 2025$691.7M
$4.6M$691.7M

Free cash flow by year

2016 → 2025

FY 2016$-60.9MFY 2017$-96.0MFY 2018$-141.4MFY 2019$-181.1MFY 2020$-293.1MFY 2021$-441.9MFY 2022$-510.2MFY 2023$-469.8MFY 2024$-307.6MFY 2025$43.6M
-$60.9M$43.6M

Gross margin by year

2021 → 2025

FY 202154.7%FY 202276.3%FY 202383.4%FY 202487.8%FY 202585.1%
54.7%85.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

4

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 15, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingRadiographic Data AnnouncementJun 30, 2026Filing
  • 6-K filingArticles of Association UpdateJun 29, 2026Filing
  • 6-K filingSale of PRVJun 17, 2026Filing
  • Annual reportAnnual Report FiledJun 15, 2026Filing
  • Annual reportAnnual Report FiledJun 12, 2026Filing
  • 6-K filingArticles of AssociationJun 10, 2026Filing
  • Insider buyInsider Buy $22KSMITH SCOTT THOMAS · EVP & Chief Financial Officer · $21.9KJun 2, 2026Filing
  • Insider buyInsider Buy $56KSMITH SCOTT THOMAS · EVP & Chief Financial Officer · $55.8KJun 1, 2026Filing
  • Insider buyInsider Buy $112KBIENAIME JEAN JACQUES · Director · $111.6KJun 1, 2026Filing
  • Insider buyInsider Buy $95KBIENAIME JEAN JACQUES · Director · $95.1KMay 27, 2026Filing

Questions

Frequently asked questions

What is Ascendis Pharma A/S's market cap?

Ascendis Pharma A/S (ASND) has a market capitalization of $13.7B.

What is ASND's P/E ratio?

A meaningful P/E ratio is not available for ASND — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying ASND stock?

Yes — SEC Form 4 filings show 4 open-market insider buys and 1 sell at Ascendis Pharma A/S in the last 90 days.

Same arena

Related companies in Biotechnology

BBIO

BridgeBio Pharma, Inc.

$13.2B

EXEL

Exelixis, Inc.

$12.9B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

AXSM

Axsome Therapeutics, Inc.

$12B

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.